0RCQ.L - Nicox S.A.
| Chiusura precedente | 0,5650 |
| Aperto | 0,0000 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 0,0000 - 0,0000 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | 11.645 |
| Capitalizzazione | 16,388M |
| Beta (5 anni mensile) | 0,97 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,1670 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireNumber of voting rights as of April 30, 2023
Nicox SA Société anonyme with a registered capital of € 50,156,698 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On May 3, 2023, MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS (Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l’AMF) As of April 30, 2023 Total number of shares composing the share capital 50,156,698Total
- GlobeNewswire
Nicox’s Partner Ocumension Therapeutics Receives Priority Review Status for ZERVIATE New Drug Application in China
Press ReleaseNicox’s Partner Ocumension Therapeutics Receives Priority Review Status for ZERVIATE New Drug Application in China Nicox’s partner, Ocumension Therapeutics, announced on April 26, 2023, that they had received Priority Review Status for the New Drug Application for ZERVIATE in ChinaAccelerates the ZERVIATE® approval and launch, which are expected in China in 2024 April 28, 2023 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, COX), an internati
- GlobeNewswire
Transfer of Nicox’s shares to Euronext Growth Paris effective on April 28, 2023
Press Release Transfer of Nicox’s shares to Euronext Growth Paris effective on April 28, 2023 April 26, 2023 – release at 9:00 am CETSophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that the transfer of the listing of the securities issued by the Company from the Euronext Paris regulated market (compartment C) to the Euronext Growth Paris multilateral trading facility (the “Transfer”), will be effective as from the tra
- GlobeNewswire
New Data on Two Nicox’s Assets, NCX 470 and NCX 1728, Presented at ARVO 2023
Press ReleaseNew Data on Two Nicox’s Assets, NCX 470 and NCX 1728, Presented at ARVO 2023April 26, 2023 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that studies highlighting nonclinical data on NCX 470 and NCX 1728 have been presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2023 being held April 23-27, 2023 in New Orleans, LA, United States.Poster t
- GlobeNewswire
Number of voting rigts as of April 24, 2023
Nicox SA Société anonyme with a registered capital of € 50,156,698 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On April 24, 2023, MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS (Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l’AMF) As of April 24, 2023 Total number of shares composing the share capital 50,156,698To
- GlobeNewswire
Nicox: 2023 Ordinary Shareholder Meeting to be held on June 1st, 2023
Press ReleaseNicox: 2023 Ordinary Shareholder Meeting to be held on June 1st, 2023April 24, 2023 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, convenes an ordinary shareholder meeting on Thursday June 1, 2023 at 2:00 pm CEST in the offices of BuroClub - Drakkar 2 - Bâtiment D - 2405 route des Dolines - 06560 Valbonne Sophia Antipolis - France.The documents mentioned in articles R.22.10-23 of the French Code
- GlobeNewswire
Nicox Provides First Quarter 2023 Financial and Business Highlights
Press ReleaseNicox Provides First Quarter 2023 Financial and Business Highlights Net revenue of €0.8 million for the first quarter of 2023 Cash position of €21.4 million as of March 31, 2023 April 19, 2023 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided financial and business highlights for the first quarter 2023 for Nicox SA and its subsidiaries (the “Nicox Group”).First Quarter 2023 Financial
- GlobeNewswire
Additional Future Royalty Revenue Stream for Nicox from 2024 following New Drug Application Submission for ZERVIATE in China
Press ReleaseAdditional Future Royalty Revenue Stream for Nicox from 2024 following New Drug Application Submission for ZERVIATE in China Nicox’s partner, Ocumension Therapeutics, submits a New Drug Application for ZERVIATE in ChinaZERVIATE® approval and launch expected in China in 2024Additional future royalty revenue stream for Nicox with Ocumension forecasting potential annual net sales of >$100 million within 7 years April 14, 2023 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (E
- GlobeNewswire
Publication of the Number of Shares Composing the Share Capital and of the Total Number of Voting Rights as of March 31, 2023
Nicox SA Société anonyme with a registered capital of € 50,156,698 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On April 3, 2023, MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS (Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l’AMF) As of March 31, 2023 Total number of shares composing the share capital 50,156,698Tot
- GlobeNewswire
Nicox Announces Presentations of Additional NCX 470 Data at the Upcoming World Glaucoma Congress
Press ReleaseNicox Announces Presentations of Additional NCX 470 Data at the Upcoming World Glaucoma CongressMarch 21, 2023 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced presentations of additional NCX 470 data at the 10th World Glaucoma Congress (WGC) which will be held from June 28 to July 1st, 2023 in Rome, Italy.Details of the presentations:Poster Title: Effects of NCX 470, a Nitric Oxide
- GlobeNewswire
Nicox Reports 2022 Financial Results and Updates Key Future Milestones
Press ReleaseNicox Reports 2022 Financial Results and Updates Key Future Milestones Net revenue of €3.3 million in 2022 Cash position of €27.7 million as of December 31, 2022 March 20, 2023 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced the financial and operating results for Nicox and its subsidiaries (the “Nicox Group”) for the year ended December 31, 2022, as approved by the Board of Direct
- GlobeNewswire
Nicox to Present at Upcoming Scientific Conferences
Press ReleaseNicox to Present at Upcoming Scientific ConferencesMarch 3, 2023 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced a number of presentations at key ophthalmology conferences including the American Glaucoma Society (AGS) Annual Meeting 2023 and the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2023.Details of the presentations (all U.S. local times) AGS 20
- GlobeNewswire
Number of voting rights as of February 28, 2023
Nicox SA Société anonyme with a registered capital of € 50,156,698 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On March 1, 2023, MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS (Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l’AMF) As of February 28, 2023 Total number of shares composing the share capital 50,156,698
- GlobeNewswire
Nicox: Ordinary Shareholder Meeting of February 28, 2023 - Approval of all Resolutions
Press ReleaseNicox: Ordinary Shareholder Meeting of February 28, 2023 - Approval of all ResolutionsMarch 1st, 2023 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that all the resolutions submitted to the Ordinary Shareholder Meeting of the Company held yesterday, have been voted. The shareholders have approved the transfer of the listing of securities issued by the Company from compartment C of
- GlobeNewswire
Nicox’s Ordinary Shareholder Meeting to be held on February 28, 2023
Press ReleaseNicox’s Ordinary Shareholder Meeting to be held on February 28, 2023February 13, 2023 Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, informs its shareholders that the Ordinary Shareholder meeting for the proposed Transfer of the listing of Nicox’s securities the Euronext Growth Paris market convened on first call on Tuesday February 14, 2023 cannot be held as the quorum required by law will not be reached. The shareholde
- GlobeNewswire
Number of voting rights as of January 31, 2023
Nicox SA Société anonyme with a registered capital of € 50,100,448 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On February 1, 2023, MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS (Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l’AMF) As of January 31, 2023 Total number of shares composing the share capital 50,156,6
- GlobeNewswire
Nicox to Participate in Financial, Pharmaceutical Industry and Scientific Events in H1 2023
Press ReleaseNicox to Participate in Financial, Pharmaceutical Industry and Scientific Events in H1 2023January 24, 2023 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today that members of the management team will participate in the following financial, pharmaceutical industry and scientific conferences in Europe and U.S. in the coming months: Financial and Pharmaceutical Industry conferences MidCap Event -
- GlobeNewswire
Nicox Provides Fourth Quarter 2022 Financial Highlights
Press ReleaseNicox Provides Fourth Quarter 2022 Financial Highlights Net revenue €1.0 million for fourth quarter 2022, and €3.3 million for the full year 2022; cash of €27.7 million on December 31, 2022Fourth quarter 2022 U.S. prescriptions for VYZULTA® increased by 25% over fourth quarter 2021 January 18, 2023 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided financial highlights for the fourth q
- GlobeNewswire
Number of voting rights as of January 9, 2023
Nicox SA Société anonyme with a registered capital of € 50,100,448 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On January 9, 2023, MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS (Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l’AMF) As of January 09, 2023 Total number of shares composing the share capital 50,100,44
- GlobeNewswire
Nicox Announces Proposed Move to Euronext Growth Paris
Press Release Nicox Announces Proposed Move to Euronext Growth Paris Intention to transfer listing from the Euronext Paris regulated market to Euronext Growth Paris Ordinary shareholder meeting convened on February 14, 2023 January 9, 2023 – release at 7:30 am CETSophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced its intention to move its listing from the Euronext Paris regulated market to Euronext Growth Paris and conve
- GlobeNewswire
Nicox: Half-year liquidity contract statement with Kepler Cheuvreux
Press Release Nicox: Half-year liquidity contract statement with Kepler Cheuvreux January 6, 2023 – release at 7:30 am CETSophia Antipolis, France Under the liquidity contract entered into between NICOX and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st 2022: 288,965 shares€ 22,074.60 Number of executions on buy side on semester: 274Number of executions on sell side on semester: 195Traded volume on buy side on semester: 155,703 shares for € 262,378.3
- GlobeNewswire
Number of voting rights as of December 31, 2022
Nicox SA Société anonyme with a registered capital of € 50,100,448 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On January 3, 2023, MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS (Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l’AMF) As of December 31, 2022 Total number of shares composing the share capital 50,100,4
- GlobeNewswire
Number of voting rights as of November 30, 2022
Nicox SASociété anonyme with a registered capital of € 50,100,448 Head Office:DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On December 1, 2022, MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS (Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l’AMF) As of November 30, 2022Total number of shares composing the share capital50,100,448T
- GlobeNewswire
Nicox Raises €10 Million in Private Placement
Press Release Nicox Raises €10 Million in Private Placement Net proceeds from the private placement to extend the cash runway to mid-May 2024Warrants to be issued in the private placement could provide an additional €11.6 million proceeds if they were to be fully exercised November 22, 2022 – release at 7:30 am CETSophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced a financing through a private placement via the issuance
- GlobeNewswire
Nicox Raises €10 Million in Private Placemen
Press Release Nicox Raises €10 Million in Private Placement Net proceeds from the private placement to extend the cash runway to mid-May 2024Warrants to be issued in the private placement could provide an additional €11.6 million proceeds if they were to be fully exercised November 22, 2022 – release at 7:30 am CETSophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced a financing through a private placement via the issuance